Evidence map›Paper›PMID 35817837›Full record

ArticleScientific reports2022

The effectiveness of 20 μg hepatitis B vaccine used for the prevention of HBV vertical transmission.

Guo Yonghao, Chen Yanping, Dou Qiaohua, Feng Daxing, Zhang Yanyang, Zhao Dongyang, Guo Wanshen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. The Role of HBx Protein in Diseases Beyond the Liver.Infection and drug resistance · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Guo Yonghao *Henan Provincial Center for Disease Control and Prevention, Zhengzhou, 450016, China.
Chen Yanping *College of Public Health, Zhengzhou University, Zhengzhou, 450001, China.
Dou QiaohuaHenan Provincial Center for Disease Control and Prevention, Zhengzhou, 450016, China.
Feng DaxingHenan Provincial Center for Disease Control and Prevention, Zhengzhou, 450016, China.
Zhang YanyangHenan Provincial Center for Disease Control and Prevention, Zhengzhou, 450016, China.
Zhao DongyangHenan Provincial Center for Disease Control and Prevention, Zhengzhou, 450016, China.
Guo WanshenHenan Provincial Center for Disease Control and Prevention, Zhengzhou, 450016, China. gwscdc@126.com.
Henan Provincial Center for Disease Control and Prevention · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To evaluate the efficiency of a 20 μg hepatitis B vaccine(HepB) for disease prevention in two counties in Henan Province, China. A questionnaire was designed to examine the information of hepatitis B surface antigen (HBsAg) positive pregnant women, and their blood samples were collected to test for hepatitis B e antigen (HBeAg), hepatitis B e antibody, and hepatitis B virus (HBV) DNA. Three doses of 20 μg HepB and one dose of hepatitis B immune globulin(HBIG) were administered to newborns. Blood samples were collected from children one month after their complete immunization to test for HBsAg and hepatitis B surface antibody(HBsAb). A total of 419 HBsAg positive-pregnant women and 430 newborns were investigated. The average age of pregnant women was 29.6 ± 4.3 years, with an HBeAg positive rate of 29.1% (122/419). All newborns received their first dose of 20 μg hepatitis B vaccine and 100 IU HBIG within 12 h after birth. Six infants (1.9%, 6/319) tested positive for HBsAg and negative for HBsAb after one month of receiving the three basic doses of HepB. The geometric mean concentration(GMC) of HBsAb-positive infants was 861.6 mIU/mL, and their HBsAb antibody titers decreased with age. Immunization of children born to HBsAg-positive mothers with 20 μg HepB got the satisfactory effect on preventing mother-to-child transmission.

Indexed as

Hepatitis BPregnancy Complications, InfectiousAdultFemaleHepatitis B AntibodiesHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B VaccinesHepatitis B virusHumansInfantInfant, NewbornInfectious Disease Transmission, VerticalPregnancyHepatitis B AntibodiesHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B Vaccines

Identifiers

PMID35817837
PMCPMC9273617
OpenAlexW4285022708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.